Three Infringement Tiers and Fine Bands under Ley 90
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Articles 35 to 37 of Ley N° 90 sort infringements into three tiers: minor (leves), serious (graves) and very serious (gravísimas). Article 44 attaches the fine ranges: minor B/.500.00 to B/.5,000.00, serious B/.5,001.00 to B/.50,000.00, and very serious from B/.50,001.00 upwards. The first item in the very serious tier is selling devices without sanitary registration, save for the exceptions the law authorises. In addition, Article 34 separately prohibits the repackaging, relabelling and reconditioning of devices.
- Three tiers, three fine bands — the bands are contiguous, so the tier into which conduct falls determines the exposure before any mitigating factor is considered.
- Unregistered sale leads the top tier — the most severe classification is reserved for placing devices on the market without the product credential.
- Six sanctions, not one — Article 39 permits a warning, suspension or cancellation of credentials, temporary closure and a fine, and they may be applied together.
- Vigilance failure is punishable — concealing or failing to report alerts, recalls and adverse events is itself an infringement under Article 35.
- Scope breaches are serious — trading without a licence, or outside the authorised scope, sits in the serious tier under Article 36.
- Repackaging is prohibited outright — Article 34 is a standalone prohibition, not a labelling rule to be managed by procedure.
2. Legal basis
Ley N° 90 of 26 December 2017 (Gaceta 28433-B) contains the whole penalty framework. Article 34 states the prohibition on repackaging, Articles 35 to 37 define the three tiers, Article 39 lists the sanctions, Article 40 the factors that determine their measure, Article 41 the precautionary measures, Article 42 the appeal route and Article 44 the fine bands.
| Ley N° 90 (26 December 2017, Gaceta 28433-B) | Article 34 | Prohibits the repackaging (reempacado), relabelling (reetiquetado) and reconditioning (reacondicionamiento) of devices and related products |
| Same | Article 35 | Minor infringements: 1. breach of the provisions prohibiting itinerant sales; 2. deliberately concealing or failing to report in time information on alerts, voluntary recalls, adverse events and potential adverse events relating to products it manufactures, distributes or sells |
| Same | Article 36 | Serious infringements, six in number: 1. selling products that differ from the documents and information submitted and approved for the sanitary registration; 2. obstructing investigations and inspections; 3. selling products whose labels omit the expiry date where applicable; 4. displaying and selling expired devices and related products; 5. holding devices and related products of unknown origin; 6. operating premises without the corresponding operating licence, or engaging in unauthorised commercial activity with devices and related products |
| Same | Article 37 | Very serious infringements, four in number: 1. selling products without sanitary registration, except for the exceptions authorised by the law; 2. manufacturing, importing and storing without prior notification to DNDM, and distributing or delivering contaminated, deteriorated, counterfeit or adulterated products; 3. falsifying or adulterating information, declarations or documents in order to obtain an operating licence, sanitary registration, CVT, GMP, storage or distribution certificate or free sale certificate; 4. falsifying or adulterating an operating licence, sanitary registration, CCT, GMP, storage or distribution certificate or free sale certificate |
| Same | Article 39 | Six available sanctions: 1. written warning; 2. suspension or cancellation of the CVT; 3. suspension or cancellation of the product sanitary registration; 4. suspension or cancellation of the operating licence; 5. temporary stoppage of activities or closure of premises; 6. fine |
| Same | Article 40 | Factors in setting the penalty: the degree of harm caused to persons, the benefit obtained through the infringement, and whether the conduct is repeated |
| Same | Article 44 | Fine bands: minor B/.500.00 to 5,000.00; serious B/.5,001.00 to 50,000.00; very serious from B/.50,001.00 |
| Same | Article 41 | DNDM may adopt precautionary measures: publication of information, temporary closure of premises, seizure or immobilisation of products; the police commissioner is obliged to provide assistance |
| Same | Article 42 | Penalties may be challenged by reconsideration (reconsideración) and appeal (apelación), both granted with devolutive effect; the administrative route is exhausted once the appeal is decided |
3. Expert insights
Insight one: the clash between Article 37, item 1, and the moratorium is the largest grey area in Panamanian compliance. The first very serious infringement is selling products without sanitary registration, save for the exceptions the law authorises, yet sanitary registrations are not being issued as a matter of routine (Article 18 of Ley 92). How the provision is currently applied must be read from the position of DNDM and customs at the time (practical estimate). For a company the practical conclusion is that credential status has to be documented: holding written proof of a CCT, an inscription certificate or an exception authorisation is the basic defence against an allegation under this item, and an undocumented assumption that the credential was not needed is not a defence at all.
Insight two: Article 35, item 2, makes late vigilance reporting a punishable infringement, a comparatively strict position for Central America. The article penalises deliberately concealing or failing to report alerts, voluntary recalls, adverse events and potential adverse events. Combined with the seventy-two hour emergency reporting duty in Article 56 of DE 490, vigilance in Panama is a hard obligation supported by a penalty rather than an aspiration expressed in guidance. The word deliberately narrows the mental element for concealment, but failure to report in time does not depend on intent, so the exposure arises from process failure as much as from misconduct.
Insight three: Article 36, item 6, classifies both unlicensed operation and out-of-scope operation as serious. The item catches operating premises without the corresponding licence and engaging in unauthorised commercial activity with devices. This corresponds to Article 69, item 3, of DE 490, which makes trading outside the authorised scope without reporting it to DNDM a ground for suspension. The two provisions reinforce each other: extending a product range without updating the licence is not an administrative oversight to be regularised later but a serious infringement in its own right, carrying consequences on both the penalty and the licence side.
Insight four: Article 39 offers six sanctions that may be imposed together, and the fine is only one of them. The official text reads serán objeto de una o más de las sanciones siguientes, one or more of the following sanctions. Suspension or cancellation of the operating licence under item 4, and temporary closure of premises under item 5, are far more damaging than a fine, particularly when read with the knock-on consequence in Article 69 of DE 490, under which loss of the licence removes the marketing qualification of every product held by the entity. Assessing penalty risk by reference to the fine band alone therefore understates the exposure by a wide margin.
4. Practical recommendations
- Document credential status throughout, whether CCT, inscription certificate or exception authorisation, as the basis for answering an allegation under Article 37, item 1.
- Establish a separate vigilance reporting process with time controls no weaker than the seventy-two hour standard in Article 56 of DE 490.
- Complete the licence update before extending the product range, rather than trading first and regularising afterwards.
- When assessing penalty risk, evaluate the knock-on effect of suspension or cancellation of the licence ahead of the fine amount.
- On receipt of a penalty decision, file reconsideration and appeal within the statutory period under Article 42, noting that both are granted with devolutive effect.
- Review labelling and expiry controls against Article 36, items 3 and 4, since these are the serious infringements most often generated by warehouse practice.
5. Verification checklist
- □ Three prohibitions under Article 34 recorded (repackaging, relabelling, reconditioning)
- □ Two minor infringements under Article 35 reviewed
- □ Six serious infringements under Article 36 reviewed
- □ Four very serious infringements under Article 37 reviewed
- □ Three fine bands under Article 44 recorded
- □ Appeal route confirmed (Article 42, reconsideration and appeal)
- □ Precautionary measure exposure under Article 41 understood
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Panamanian market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us